R-FND Followed by Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance in Untreated High-Risk Follicular Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Initial Report of a Phase II Study With R-FND Followed by Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance in Patients With Untreated High-Risk Follicular Lymphoma
Leukemia and Lymphoma 2020 Sep 14;[EPub Ahead of Print], F Samaniego, P McLaughlin, SS Neelapu, L Feng, M Fanale, L Nastoupil, MA Rodriguez, B Pro, E Taylor, FB Hagemeister, N FowlerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.